Control of hepatitis C: A medicinal chemistry perspective

Journal of Medicinal Chemistry

Volumn 48, Issue 1, 2005, Pages 1-20

  Gordon, Christopher P ^a   Keller, Paul A ^a  

^a UNIVERSITY OF WOLLONGONG   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

2 [(2,4 DICHLOROBENZOYL)(3 TRIFLUOROMETHYLBENZYL)AMINO] 3 PHENYLPROPIONIC ACID; 2 [(5 BENZOFURAN 2 YLTHIOPHEN 2 YLMETHYL)(2,4 DICHLOROBENZOYL)AMINO] 3 PHENYLPROPIONIC ACID; 4,5,6,7 TETRABROMOBENZOTRIAZOLE; 5,6 DICHLORO 1 (BETA DEXTRO RIBOFURANOSYL)BENZOTRIAZOLE; ALPHA INTERFERON; ANTIVIRUS AGENT; BENZAMIDE DERIVATIVE; BENZIMIDAZOLE DERIVATIVE; BENZOTHIADIAZINE DERIVATIVE; BENZOXAZOLE DERIVATIVE; BETA DEXTRO 2' METHYLRIBOFURANOSYLGUANOSINE; CARBAZOLE DERIVATIVE; CARBOXYLIC ACID DERIVATIVE; EPIRUBICIN; MURAYAQUINONE; NOGALAMYCIN; PACLITAXEL; PHENAZINE; RIBAVIRIN; RIBAVIRIN DIPHOSPHATE; RIBAVIRIN TRIPHOSPHATE; SCH 351633; SCH 68631; THIAZOLIDINE DERIVATIVE; THIOMORPHOLINE; TRIFLUOPERAZINE; UNCLASSIFIED DRUG; VIRUS ENZYME;

AMINO ACID SEQUENCE; COMPETITIVE INHIBITION; CRYSTAL STRUCTURE; DRUG BINDING SITE; DRUG EFFICACY; DRUG POTENCY; DRUG RESPONSE; DRUG SYNTHESIS; DRUG TARGETING; DRUG TOLERABILITY; ENZYME INHIBITION; HEPATITIS C; HUMAN; IC 50; NONHUMAN; PENICILLIUM; REVIEW; SIDE EFFECT; STREPTOMYCES; STRUCTURE ACTIVITY RELATION; VIRUS GENOME;

AMINO ACID SEQUENCE; ANTIVIRAL AGENTS; DRUG DESIGN; ENZYME INHIBITORS; HEPATITIS C; HUMANS; MOLECULAR MIMICRY; MOLECULAR SEQUENCE DATA; NUCLEOSIDE-TRIPHOSPHATASE; NUCLEOSIDES; PROTEASE INHIBITORS; RNA HELICASES; RNA, VIRAL; STRUCTURE-ACTIVITY RELATIONSHIP; VIRAL NONSTRUCTURAL PROTEINS;

EID: 12144260229     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0400101     Document Type: Review

References (166)

1. Hepatitis C-Global prevalence (update). Weekly Epidemiol. Rec. 2000, 75, 18-19.
2. Choo, Q. L.; Kuo, G.; Weiner, A. J.; Overby, L. R.; Bradley, D. W.; Houghton, M. Isolation of a cDNA clone derived from a bloodborne non-A, non-B viral hepatitis genome. Science 1989, 244, 359-362.
3. Hoofnagle, J. H. Hepatitis C: the clinical spectrum of disease. Hepatology 1997, 26, 15S-20S.
4. Bartenschlager, R.; Lohmann, V. Novel cell culture systems for the hepatitis C virus. Antiviral Res. 2001, 52, 1-17.
5. Buckwold, V. E.; Beer, B. E.; Donis, R. O. Bovine viral diarrhea virus as a surrogate model of hepatitis C virus for the evaluation of antiviral agents. Antiviral Res. 2003, 60, 1-15.
6. Zein, C. O.; Zein, N. N. Advances in therapy for hepatitis C infection. Microbes Infect. 2002, 4, 1237-1246.
7. Durantel, D.; Escuret, V.; Zoulim, F. Current and emerging therapeutic approaches to hepatitis C infection. Expert Rev. Anti-Infect. Ther. 2003, 1, 441-454.
8. Walker, M. A. Hepatitis C virus: an overview of current approaches and progress. Drug Discovery Today 1999, 4, 518-529.
9. Poordad, F. F.; Tran, T.; Martin, P. Developments in hepatitis C therapy during 2000-2002. Expert Opin. Emerging Drugs 2003, 8, 9-25.
10. Rivas-Estilla, A. M.; Panduro, A. Molecular mechanisms of hepatitis C virus, potential therapeutic targets. Rev. Invest. Clin. 2003, 55, 51-64.
11. De Francesco, R.; Tomei, L.; Altamura, S.; Summa, V.; Migliaccio, G. Approaching a new era for hepatitis C virus therapy, inhibitors of the NS3-4A serine protease and the NS5B RNA-dependent RNA polymerase. Antiviral Res. 2003, 58, 1-16.
12. Tan, S.-L.; Pause, A.; Shi, Y.; Sonenberg, N. Hepatitis C therapeutics: current status and emerging strategies. Nat. Rev. Drug Discovery 2002, 1, 867-881.
13. Moussalli, J.; Opolon, P.; Poynard, T. Management of hepatitis C. J. Hepatitis 1998, 5, 73-82.
14. Davis, G. L.; Wong, J. B.; McHutchison, J. G.; Manns, M. P.; Harvey, J.; Albrecht, J. Early virologic response to treatment with peginterferon α-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003, 38, 645-652.
15. Wang, C.; Pflugheber, J.; Sumpter, R., Jr.; Sodora, D. L.; Hui, D.; Sen, G. C.; Gale, M., Jr. Alpha interferon induces distinct translational control programs to suppress hepatitis C virus RNA replication. J. Virol. 2003, 77, 3898-3912.
16. Sharara, A. I.; Perkins, D. J.; Misukonis, M. A.; Chan, S. U.; Dominitz, J. A.; Weinberg, J. B. Interferon (IFN)-a activation of human blood mononuclear cells in vitro and in vivo for nitric oxide synthase (NOS) type 2 mRNA and protein expression: possible relationship of induced NOS2 to the anti-hepatitis C effects of IFN-α in vivo. J. Exp. Med. 1997, 186, 1495-1502.
17. Scott, L. J.; Perry, C. M. Interferon-α-2b plus ribavirin: A review of its use in the management of chronic hepatitis C. Drugs 2002, 62, 507-556.
18. Medina, J.; Garcia-Buey, L.; Moreno-Monteagudo, J. A.; Trapero-Marugan, M.; Moreno-Otero, R. Therapeutic advantages of pegylation of interferon alpha in chronic hepatitis C. Rev. Esp. Enferm. Apar. Dig. 2003, 95, 561-574.
19. Perez-Olmeda, M.; Nunez, M.; Romero, M.; Gonzalez, J.; Castro, A.; Arribas, J. R.; Pedreira, J.; Barreiro, P.; Garcia-Samaniego, J.; Martin-Carbonero, L.; Jimenez-Nacher, I.; Soriano, V. Pegylated IFN-α2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients. AIDS 2003, 17, 1023-1028.
20. Fried Michael, W. Side effects of therapy of hepatitis C and their management. Hepatology 2002, 36, S237-S244.
21. Matsuura, Y. Expression and characterization of hepatitis C virus (HCV) proteins. Uirusu 1995, 45, 105-115.
22. Ogata, N.; Alter, H. J.; Miller, R. H.; Purcell, R. H. Nucleotide sequence and mutation rate of the H strain of hepatitis C virus. Proc. Nat. Acad. Sci. U.S.A. 1991, 88, 3392-3396.
23. Reed, K. E.; Rice, C. M. Expression and characterization of the HCV NS2 protease. Metod Mol. Med. 1998, 19, 331-342.
24. Pallaoro, M.; Lahm, A.; Biasiol, G.; Brunetti, M.; Nardella, C.; Orsatti, L.; Bonelli, F.; Orru, S.; Narjes, F.; Steinkuhler, C. Characterization of the hepatitis C virus NS2/3 processing reaction by using a purified precursor protein. J. Virol. 2001, 75, 9939-9946.
25. Wilkinson, T. Hepatitis C virus: Prospects for future therapies. Curr. Opin. Invest. Drugs 2001, 2, 1516-1522.
26. Melcher, S. E.; Wilson, T. J.; Lilley, D. M. J. The dynamic nature of the four-way junction of the hepatitis C virus IRES. RNA 2003, 9, 809-820.
27. Buratti, E.; Gerotto, M.; Pontisso, P.; Alberti, A.; Tisminetzky, S. G.; Baralle, F. E. In vivo translational efficiency of different hepatitis C virus 5′-UTRs. FEBS Lett. 1997, 411, 275-280.
28. Neuman, M. G.; Benhamou, J.-P.; Malkiewicz, I. M.; Akremi, R; Shear, N. H.; Asselah, T.; Ibrahim, A.; Boyer, N.; Martinot-Peignoux, M.; Jacobson-Brown, P.; Katz, G. G.; Le Breton, V.; Le Guludec, G.; Suneja, A.; Marcellin, P. Cytokines as predictors for sustained response and as markers for immunomodulation in patients with chronic hepatitis C. Clin. Biochem. 2001, 34, 173-182.
29. Urbani, A.; Bianchi, E.; Narjes, F.; Tramontano, A.; De Francesco, R.; Steinkuhler, C.; Pessi, A. Substrate specificity of the hepatitis C virus serine protease NS3. J. Biol. Chem. 1997, 272, 9204-9209.
30. Kim, S. Y.; Park, K. W.; Lee, Y. J.; Back, S. H.; Goo, J. H.; Park, O. K.; Jang, S. K.; Park, W. J. In vivo determination of substrate specificity of hepatitis C virus NS3 protease: genetic assay for site-specific proteolysis. Anal. Biochem. 2000, 284, 42-48.
31. Kolykhalov, A. A.; Agapov, E. V.; Rice, C. M. Specificity of the hepatitis C virus NS3 serine protease: effects of substitutions at the 3/4A, 4A/4B, 4B/5A, and 5A/5B cleavage sites on polyprotein processing. J. Virol. 1994, 68, 7525-7533.
32. Schlechter, I.; Berger, A. On the size of the active site in proteases. I. Papain. Biochem. Biophys. Res. Commun. 1987, 27, 157-162.
33. Grakoui, A.; McCourt, D. W.; Wychowski, C.; Feinstone, S. M.; Rice, C. M. Characterization of the hepatitis C virus-encoded serine proteinase: Determination of proteinase-dependent polyprotein cleavage sites. J. Virol. 1993, 67, 2832-2843.
34. Pizzi, E.; Tramontano, A.; Tomei, L.; La Monica, N.; Failla, C.; Sardana, M.; Wood, T.; De Francesco, R. Molecular model of the specificity pocket of the hepatitis C virus protease: implications for substrate recognition. Proc. Natl. Acad. Sci. U.S.A. 1994, 91, 888-892.
35. Colarusso, S.; Gerlach, B.; Koch, U.; Muraglia, E.; Conte, I.; Stansfield, I.; Matassa, V. G.; Narjes, F. Evolution, synthesis and SAR of tripeptide α-ketoacid inhibitors of the hepatitis C virus NS3/NS4A serine protease. Bioorg. Med. Chem. Lett. 2002, 12, 705-708.
36. De Francesco, R.; Urbani, A.; Nardi, M. C.; Tomei, L.; Steinkuehler, C.; Tramontano, A. A zinc binding site in viral serine proteinases. Biochemistry 1996, 35, 13282-13287.
37. Katz, B. A.; Clark, J. M.; Finer-Moore, J. S.; Jenkins, T. E.; Johnson, C. R.; Ross, M. J.; Luong, C.; Moore, W. R.; Stroud, R. M. Design of potent selective zinc-mediated serine protease inhibitors. Nature 1998, 391, 608-612.
38. Archer, S. J.; Camac, D. M.; Wu, Z. J.; Farrow, N. A.; Domaille, P. J.; Wasserman, Z. R.; Bukhtiyarova, M.; Rizzo, C.; Jagannathan, S.; Mersinger, L. J.; Kettner, C. A. Hepatitis C Virus NS3 Protease Requires Its NS4A Cofactor Peptide for Optimal Binding of a Boronic Acid Inhibitor As Shown by NMR. Chem. Biol. 2002, 9, 79-92.
39. Kwong, A. D.; Kim, J. L.; Rao, G.; Lipovsek, D.; Raybuck, S. A. Hepatitis C virus NS3/4A protease. Antiviral Res. 1998, 40, 1-18.
40. De Francesco, R.; Steinkuhler, C. Structure and function of the hepatitis C virus NS3-NS4A serine proteinase. Curr. Top. Microbiol. Immunol. 2000, 242, 149-169.
41. Steinkuhler, C.; Koch, U.; Narjes, F.; Matassa, V. G. Hepatitis C virus serine protease inhibitors: current progress and future challenges. Curr. Med. Chem. 2001, 8, 919-932.
42. Llinas-Brunet, M.; Bailey, M.; Fazal, G.; Goulet, S.; Halmos, T.; Laplante, S.; Maurice, R.; Poirier, M.; Poupart, M. A.; Thibeault, D.; Wernic, D.; Lamarre, D. Peptide-based inhibitors of the hepatitis C virus serine protease. Bioorg. Med. Chem. Lett. 1998, 8, 1713-1718.
43. Steinkuhler, C.; Biasiol, G.; Brunetti, M.; Urbani, A.; Koch, U.; Cortese, R.; Pessi, A.; De Francesco, R. Product inhibition of the hepatitis C virus NS3 protease. Biochemistry 1998, 37, 8899-8905.
44. Ingallinella, P.; Altamura, S.; Bianchi, E.; Taliani, M.; Ingenito, R.; Cortese, R.; De Francesco, R.; Steinkuehler, C.; Pessi, A. Potent Peptide Inhibitors of Human Hepatitis C Virus NS3 Protease Are Obtained by Optimizing the Cleavage Products. Biochemistry 1998, 37, 8906-8914.
45. Beaulieu, P. L.; Llinas-Brunet, M. Therapies for hepatitis C infection: targeting the non-structural proteins of HCV. Curr. Med. Chem. 2002, 1, 163-176.
46. Steinkuhler, C.; Koch, U.; De Francesco, R.; Pessi, A. The proteinases encoded by hepatitis C virus as therapeutic targets. Handb. Exp. Pharmacol. 2000, 140, 75-94.
47. Kim, J. L.; Morgenstern, K. A.; Lin, C.; Fox, T.; Dwyer, M. D.; Landro, J. A.; Chambers, S. P.; Markland, W.; Lepre, C. A. Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide. Cell 1996, 87, 343-355.
48. Di Marco, S.; Rizzi, M.; Volpari, C.; Walsh, M. A.; Narjes, F.; Colarusso, S.; De Francesco, R.; Matassa, V. G.; Sollazzo, M. Inhibition of the hepatitis C virus NS3/4A protease: The crystal structures of two protease-inhibitor complexes. J. Biol. Chem. 2000, 275, 7152-7157.
49. Koch, U.; Biasiol, G.; Brunetti, M.; Fattori, D.; Pallaoro, M.; Steinkuhler, C. Role of charged residues in the catalytic mechanism of hepatitis C virus NS3 protease: electrostatic precollision guidance and transition-state stabilization. Biochemistry 2001, 40, 631-640.
50. Lai, C.-S.; Wang, T. Modification of NSAIDs by sulfur-containing functional groups. U.S. 6,429,223, 2002.
51. Emery, P.; Bradley, H.; Gough, A.; Arthur, V.; Jubb, R.; Waring, R. Increased prevalence of poor sulphoxidation in patients with rheumatoid arthritis: effect of changes in the acute phase response and second line drug treatment. Ann. Rheum. Dis. 1992, 51, 318-320.
52. Narjes, F.; Brunetti, M.; Colarusso, S.; Gerlach, B.; Koch, U.; Biasiol, G.; Fattori, D.; De Francesco, R.; Matassa, V. G.; Steinkuehler, C. α-Ketoacids Are Potent Slow Binding Inhibitors of the Hepatitis C Virus NS3 Protease. Biochemistry 2000, 39, 1849-1861.
53. Llinas-Brunet, M.; Bailey, M.; Fazal, G.; Ghiro, E.; Gorys, V.; Goulet, S.; Halmos, T.; Maurice, R.; Poirier, M.; Poupart, M. A.; Rancourt, J.; Thibeault, D.; Wernic, D.; Lamarre, D. Highly potent and selective peptide-based inhibitors of the hepatitis C virus serine protease: towards smaller inhibitors. Bioorg. Med. Chem. Lett. 2000, 10, 2267-2270.
54. Johansson, A.; Hubatsch, I.; Akerblom, E.; Lindeberg, G.; Winiwarter, S.; Danielson, U. H.; Hallberg, A. Inhibition of hepatitis C virus NS3 protease activity by product-based peptides is dependent on helicase domain. Bioorg. Med. Chem. Lett. 2001, 11, 203-206.
55. Frecer, V.; Kabelac, M.; De Nardi, P.; Pricl, S.; Miertus, S. Structure-based design of inhibitors of NS3 serine protease of hepatitis C virus. J. Mol. Graphics Modell. 2003, 22, 209-220.
56. Goudreau, N.; Cameron, D. R.; Bonneau, P.; Gorys, V.; Plouffe, C.; Poirier, M.; Lamarre, D.; Llinas-Brunet, M. NMR Structural Characterization of Peptide Inhibitors Bound to the Hepatitis C Virus NS3 Protease: Design of a New P2 Substituent. J. Med. Chem. 2004, 47, 123-132.
57. Barbato, G.; Cicero, D. O.; Nardi, M. C.; Steinkuehler, C.; Cortese, R.; De Franscesco, R.; Bazzo, R. The solution structure of the N-terminal proteinase domain of the hepatitis C virus (HCV) NS3 protein provides new insights into its activation and catalytic mechanism. J. Mol. Biol. 1999, 289, 371-384.
58. Barbato, G.; Cicero, D. O.; Cordier, F.; Narjes, F.; Gerlach, B.; Sambucini, S.; Grzesiek, S.; Matassa, V. G.; De Franscesco, R.; Bazzo, R. Inhibitor binding induces active site stabilization of the HCV NS3 protein serine protease domain. EMBO J. 2000, 6, 1195-1206.
59. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Delivery Rev. 2001, 46, 3-26.
60. Tsantrizos, Y. S.; Cameron, D. R.; Faucher, A.-m.; Ghiro, E.; Goudreau, N.; Halmos, T.; Llinas-brunet, M. Preparation of macrocyclic peptides active against the hepatitis C virus. WO 2000059929, 2000.
61. Tsantrizos, Y. S.; Bolger, G.; Bonneau, P.; Cameron, D. R.; Goudreau, N.; Kukolj, G.; LaPlante, S. R.; Llinas-Brunet, M.; Nar, H.; Lamarre, D. Macrocyclic inhibitors of the NS3 protease as potential therapeutic agents of hepatitis C virus infection. Angew. Chem., Int. Ed. 2003, 42, 1356-1360.
62. Llinas-Brunet, M.; Bailey, M. D.; Bolger, G.; Brochu, C.; Faucher, A.-M.; Ferland, J. M.; Garneau, M.; Ghiro, E.; Gorys, V.; Grand-Maitre, C.; Halmos, T.; Lapeyre-Paquette, N.; Liard, F.; Poirier, M.; Rheaume, M.; Tsantrizos, Y. S.; Lamarre, D. Structure-Activity Study on a Novel Series of Macrocyclic Inhibitors of the Hepatitis C Virus NS3 Protease Leading to the Discovery of BILN 2061. J. Med. Chem. 2004, 47 (7), 1605-1608.
63. Steinkuhler, C.; Urbani, A.; Tomei, L.; Biasiol, G.; Sardana, M.; Bianchi, E.; Pessi, A.; De Francesco, R. Activity of purified hepatitis C virus protease NS3 on peptide substrates. J. Virol. 1998, 70, 6694-6700.
64. Urbani, A.; Bianchi, E.; Narjes, F.; Tramontano, A.; De Francesco, R.; Steinkuhler, C.; Pessi, A. Substrate specificity of the hepatitis C virus serine protease NS3. J. Biol. Chem. 1997, 272, 9204-9209.
65. Zhang, R.; Mui, P. W.; Weber, P. C. Synthetic inhibitors of hepatitis C virus NS3 protease (Schering Corporation). Application WO9743310, 1997; 59 pp.
66. Landro, J. A.; Raybuck, S. A.; Luong, Y. P. C.; O'Malley, E. T.; Harbeson, S. L.; Morgenstern, K. A.; Rao, G.; Livingston, D. J. Mechanistic Role of an NS4A Peptide Cofactor with the Truncated NS3 Protease of Hepatitis C Virus: Elucidation of the NS4A Stimulatory Effect via Kinetic Analysis and Inhibitor Mapping. Biochemistry 1997, 36, 9340-9348.
67. Ingallinella, P.; Fattori, D.; Altamura, S.; Steinkuehler, C.; Koch, U.; Cicero, D.; Bazzo, R.; Cortese, R.; Bianchi, E.; Pessi, A. Prime Site Binding Inhibitors of a Serine Protease: NS3/4A of Hepatitis C Virus. Biochemistry 2002, 41, 5483-5492.
68. Colarusso, S.; Koch, U.; Gerlach, B.; Steinkuehler, C.; De Francesco, R.; Altamura, S.; Matassa, V. G.; Narjes, F. Phenethyl Amides as Novel Noncovalent Inhibitors of Hepatitis C Virus NS3/4A Protease: Discovery, Initial SAR, and Molecular Modeling. J. Med. Chem. 2003, 46, 345-348.
69. Butkiewicz, N. J.; Wendel, M.; Zhang, R.; Jubin, R.; Pichardo, J.; Smith, E. B.; Hart, A. M.; Ingram, R.; Durkin, J.; et al. Enhancement of hepatitis C virus NS3 proteinase activity by association with NS4A-specific synthetic peptides: identification of sequence and critical residues of NS4A for the cofactor activity. Virology 1996, 225, 328-338.
70. Chu, M.; Mierzwa, R.; Truumees, I.; King, A.; Patel, M.; Berrie, R.; Hart, A.; Butkiewicz, N.; DasMahapatra, B. Structure of Sch 68631: a new hepatitis C virus proteinase inhibitor from Streptomyces sp. Tetrahedron Lett. 1996, 37, 7229-7232.
71. Chu, M.; Mierzwa, R.; He, L.; King, A.; Patel, M.; Pichardo, J.; Hart, A.; Butkiewicz, N.; Puar, M. S. Isolation and structure of SCH 351633: a novel hepatitis C virus (HCV) NS3 protease inhibitor from the fungus Penicillium griseofulvum. Bioorg. Med. Chem. Lett. 1999, 9, 1949-1952.
72. Sudo, K.; Matsumoto, Y.; Matsushima, M.; Konno, K.; Shimotohno, K.; Shigeta, S.; Yokota, T. Novel hepatitis C virus protease inhibitors: 2,4,6-trihydroxy, 3-nitro-benzamide derivatives. Antiviral Chem. Chemother. 1997, 8, 541-544.
73. Sudo, K.; Matsumoto, Y.; Matsushima, M.; Fujiwara, M.; Konno, K.; Shimotohno, K.; Shigeta, S.; Yokota, T. Novel hepatitis C virus protease inhibitors: thiazolidine derivatives. Biochem. Biophys. Res. Commun. 1997, 238, 643-647.
74. Kakiuchi, N.; Komoda, Y.; Komoda, K.; Takeshita, N.; Okada, S.; Tani, T.; Shimotohno, K. Non-peptide inhibitors of HCV serine proteinase. FEBS Lett. 1998, 421, 217-220.
75. Hajduk, P. J.; Meadows, R. P.; Fesik, S. W. Discovering high-affinity ligands for proteins. Science 1997, 278, 497-499.
76. Pellecchia, M.; Meininger, D.; Dong, Q.; Chang, E.; Jack, R.; Sem, D. S. NMR-based structural characterization of large protein-ligand interactions. J. Biomol. NMR 2002, 22, 165-173.
77. Wyss, D. F.; McCoy, M. A.; Senior, M. S. NMR-based approaches for lead discovery. Curr. Opin. Drug Discovery Dev. 2002, 5, 630-647.
78. McCoy, M. A.; Wyss, D. F. Spatial localization of ligand binding sites from electron current density surfaces calculated from NMR chemical shift perturbations. J. Am. Chem. Soc. 2002, 124, 11758-11763.
79. McCoy, M. A.; Wyss, D. F. Alignment of weakly interacting molecules to protein surfaces using simulations of chemical shift perturbations. J. Biomol. NMR 2000, 18, 189-198.
80. Wyss, D. F.; Arasappan, A.; Senior, M. M.; Wang, Y.-S.; Beyer, B. M.; Njoroge, F. G.; McCoy, M. A. Non-Peptidic Small-Molecule Inhibitors of the Single-Chain Hepatitis C Virus NS3 Protease/NS4A Cofactor Complex Discovered by Structure-Based NMR Screening. J. Med. Chem. 2004, 47, 2486-2498.
81. Urvil, P. T.; Kakiuchi, N.; Zhou, D.-M.; Shimotohno, K.; Kumar, P. K. R.; Nishikawa, S. Selection of RNA aptamers that bind specifically to the NS3 protease of hepatitis C virus. Eur. J. Biochem. 1997, 248, 130-138.
82. Fukuda, K.; Vishinuvardhan, D.; Sekiya, S.; Kakiuchi, N.; Shimotohno, K.; Kumar, P. K. R.; Nishikawa, S. Specific RNA aptamers to NS3 protease domain of hepatitis C virus. Nucleic Acids Symp. Ser. 1997, 37, 237-238.
83. Biroccio, A.; Hamm, J.; Incitti, I.; De Francesco, R.; Tomei, L. Selection of RNA aptamers that are specific and high-affinity ligands of the hepatitis C virus RNA-dependent RNA polymerase. J. Virol. 2002, 76, 3688-3696.
84. Kumar, P. K. R.; Machida, K.; Urvil, P. T.; Kakiuchi, N.; Vishnuvardhan, D.; Shimotohno, K.; Taira, K.; Nishikawa, S. Isolation of RNA aptamers specific to the NS3 protein of hepatitis C virus from a pool of completely random RNA. Virology 1997, 237, 270-282.
85. Nishikawa, F.; Kakiuchi, N.; Funaji, K.; Fukuda, K.; Sekiya, S.; Nishikawa, S. Inhibition of HCV NS3 protease by RNA aptamers in cells. Nucleic Acids Res. 2003, 31, 1935-1943.
86. Piccininni, S.; Varaklioti, A.; Nardelli, M.; Dave, B.; Raney, K. D.; McCarthy, J. E. G. Modulation of the Hepatitis C Virus RNA-Dependent RNA Polymerase Activity by the Non-Structural NS3 Helicase and the NS4B Membrane Protein. J. Biol. Chem. 2002, 277, 45670-45679.
87. Wang, Q. M.; Hockman, M. A.; Staschke, K.; Johnson, R. B.; Case, K. A.; Lu, J.; Parsons, S.; Zhang, F.; Rathnachalam, R.; Kirkegaard, K.; Colacino, J. M. Oligomerization and cooperative RNA synthesis activity of hepatitis C virus RNA-dependent RNA polymerase. J. Virol. 2002, 76, 3865-3872.
88. Wang, M.; Ng, K. S.; Cherney, M.; Chan, L.; Yannopoulos, C., G.; Bedard, J.; Morin, N.; Nguyen-Ba, N.; Alaoui-Ismaili M. H.; Bethell, R. C.; James, M. N. G. Non-nucleoside analogue inhibitors bind to an allosteric site on HCV NS5B polymerase. Crystal structures and mechanism of inhibition. J. Biol. Chem. 2003, 278, 9489-9495.
89. Ago, H.; Adachi, T.; Yoshida, A.; Yamamoto, M.; Habuka, N.; Yatsunami, K.; Miyano, M. Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Struct. Fold. Des. 1999, 7, 1417-1426.
90. Bressanelli, S.; Tomei, L.; Roussel, A.; Incitti, I.; Vitale, R. L.; Mathieu, M.; De Francesco, R.; Rey, F. A. Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 13034-13039.
91. Ferrari, E.; Wright-Minogue, J.; Fang, J. W. S.; Baroudy, B. M.; Lau, J. Y. N.; Hong, Z. Characterization of soluble hepatitis C virus RNA-dependent RNA polymerase expressed in Escherichia coli. J. Virol. 1999, 73, 1649-1654.
92. Lesburg, C. A.; Cable, M. B.; Ferrari, E.; Hong, Z.; Mannarino, A. F.; Weber, P. C. Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site. Nat. Struct. Biol. 1999, 6, 937-943.
93. Hansen, J. L.; Long, A. M.; Schultz, S. C. Structure of the RNA-dependent RNA polymerase of poliovirus. Structure 1997, 5, 1109-1122.
94. Doublie, S.; Sawaya, M. R.; Ellenberger, T. An open and closed case for all polymerases. Struct. Fold. Des. 1999, 7, R31-R35.
95. Steitz, T. A. DNA polymerases: structural diversity and common mechanisms. J. Biol. Chem. 1999, 274, 17395-17398.
96. O'Farrell, D.; Trowbridge, R.; Rowlands, D.; Jager, J. Substrate complexes of hepatitis C virus RNA polymerase (HC-J4): structural evidence for nucleotide import and de-novo initiation. J. Mol. Biol. 2003, 326, 1025-1035.
97. Lau, J. Y. N.; Tam, R. C.; Liang, T. J.; Hong, Z. Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology 2002, 35, 1002-1009.
98. Crotty, S.; Maag, D.; Arnold, J. J.; Zhong, W.; Lau, J. Y.; Hong, Z.; Andino, R.; Cameron, C. E. The broad-spectrum antiviral ribonucleoside ribavirin is an RNA virus mutagen. Nat. Med. 2000, 6, 1375-1379.
99. Maag, D.; Castro, C.; Hong, Z.; Cameron, C. E. Hepatitis C virus RNA-dependent RNA polymerase (NS5B) as a mediator of the antiviral activity of ribavirin. J. Biol. Chem. 2001, 276, 46094-46098.
100. McHutchison, J. G.; Gordon, S. C.; Schiff, E. R.; Shiffman, M. L.; Lee, W. M.; Rustgi, V. K.; Goodman, Z. D.; Ling, M. H.; Cort, S.; Albrecht, J. K. Interferon α-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N. Engl. J. Med. 1998, 339, 1485-1492.
101. Manns, M. P.; McHutchison, J. G.; Gordon, S. C.; Rustgi, V. K.; Shiffman, M.; Reindollar, R.; Goodman, Z. D.; Koury, K.; Ling, M. H.; Albrecht, J. K. Peginterferon α-2b plus ribavirin compared with interferon α-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet 2001, 358, 958-965.
102. Ismaili, H. M. A.; Cheng, Y.-X.; Lavallee, J.-F.; Siddiqui, A.; Storer, R. Method for the treatment or prevention of flavivirus infections using nucleoside analogues. WO 2001060315, 2001.
103. Storer, R. Method for the treatment or prevention of Flaviviridae viral infection using nucleoside analogs. WO 2001032153, 2001.
104. Beaulieu, P. L.; Fazal, G.; Gillard, J.; Kukolj, G.; Austel, V. Preparation of benzimidazolecarboxylates and related compounds as viral polymerase inhibitors. WO 2002004425, 2002.
105. Hashimoto, H.; Mizutani, K.; Yoshida, A. Preparation of heterocyclic compounds as remedies for hepatitis C. WO 2001047883, 2001.
106. Dhanak, D.; Kaura, A. C.; Shaw, A. Preparation of 3-(1,1-dioxo-2H-benzo- 1,2,4-thiadiazin-3-yl)-2-quinolones as novel anti-infectives. WO 2001085172, 2001.
107. Dhanak, D.; Carr, T. Preparation of pyrrolidine-2,4-dicarboxylic acid derivatives as novel anti-infectives. WO 2001085720, 2001.
108. Kukolj, G.; Pause, A. Self-replicating RNA molecule from hepatitis C virus having adaptive mutations, and its uses in screening assay for HCV replication inhibitors. WO 2002052015, 2002.
109. Beaulieu, P. L.; Bos, M.; Bousquet, Y.; Fazal, G.; Gauthier, J.; Gillard, J.; Goulet, S.; LaPlante, S.; Poupart, M, A.; Lefebvre, S.; McKercher, G.; Pellerin, C.; Austel, V.; Kukolj, G. Non-nucleoside inhibitors of the hepatitis C virus NS5B polymerase: discovery and preliminary SAR of benzimidazole derivatives. Bioorg. Med. Chem. Lett. 2004, 14, 119-124.
110. Hashimoto, H.; Mizutani, K.; Yoshida, A. Preparation of substituted 1-cyclohexyl-2-phenylbenzimidazole-5-carboxylic acids as remedies for hepatitis C. WO 2003050320, 2003.
111. Altamura, S.; Tomei, L.; Koch, U.; Neuner, P. J. S.; Summa, V. Diketoacid derivatives as inhibitors of viral polymerases. WO 2000006529, 2000.
112. Colarusso, S.; Gardelli, C.; Gerlach, B.; Harper, S.; Koch, U.; Matassa, V. G.; Muraglia, E.; Narjes, F.; Ontoria, O. J. M.; Petrocchi, A.; Ponzi, S.; Stansfield, I.; Summa, V. Preparation of peptide inhibitors of hepatitis C virus NS3 protease. WO 2002079234, 2002.
113. Summa, V.; Petrocchi, A.; Pace, P.; Matassa, V. G.; De Francesco, R.; Altamura, S.; Tomei, L.; Koch, U.; Neuner, P. Discovery of α,γ- Diketo Acids as Potent Selective and Reversible Inhibitors of Hepatitis C Virus NS5b RNA-Dependent RNA Polymerase J. Med. Chem. 2004, 47 (1), 14-17.
114. Liu, D.; Wang, Y. S.; Gesell, J. J.; Wyss, D. F. Solution structure and backbone dynamics of an engineered arginine-rich subdomain 2 of the hepatitis C virus NS3 RNA helicase. J. Mol. Biol. 2001, 314, 543-561.
115. Borowski, P.; Schalinski, S.; Schmitz, H. Nucleotide triphosphatase/ helicase of hepatitis C virus as a target for antiviral therapy. Antiviral Res. 2002, 55, 397-412.
116. Gu, B.; Liu, C.; Lin-Goerke, J.; Maley, D. R.; Gutshall L. L.; Fletenberger, C. A.; Del Vecchio, A. The RNA helicase and nucleotide triphosphatase activities of the bovine viral diarrhea virus NS3 protein are essential for viral replication. J. Virol. 2000, 74, 1794-1800.
117. Matusan, A. E.; Pryor, M. J.; Davidson, A. D.; Wright, P. J. Mutagenesis of the Dengue Virus Type 2 NS3 Protein within and outside Helicase Motifs: Effectson Enzyme Activity and Virus Replication. J. Virol. 2001, 75, 9633-9643.
118. Kadare, G.; Haenni, A.-L. Virus-encoded RNA helicases. J. Virol. 1997, 71, 2583-2590.
119. Gorbalenya, A. E.; Koonin, E. V. Viral proteins containing the purine NTP-binding sequence pattern. Nucleic Acids Res. 1989, 17, 8413-8440.
120. Walker, J. E.; Saraste, M.; Runswick, M. J.; Gay, N. J. Distantly related sequences in the α- and β-subunits of ATP synthase, myosin, kinases and other ATP-requiring enzymes and a common nucleotide binding fold. EMBO J. 1982, 1, 945-951.
121. Tai, C. L.; Pan, W. C.; Liaw, S. H.; Yang, U. C.; Hwang, L. H.; Chen, D. S. Structure-based mutational analysis of the hepatitis C virus NS3 helicase. J. Virol. 2001, 75, 8289-8297.
122. Yao, N.; Hesson, T.; Cable, M.; Hong, Z.; Kwong, A. D.; Le, H. V.; Weber, P. C. Structure of the hepatitis C virus RNA helicase domain. Nat. Struct. Biol. 1997, 4, 463-467.
123. Kim, J. L.; Morgenstern, K. A.; Griffith, J. P.; Dwyer, M. D.; Thomson, J. A.; Murcko, M. A.; Lin, C.; Caron, P. R. Hepatitis C virus NS3 RNA helicase domain with a bound oligonucleotide: the crystal structure provides insights into the mode of unwinding. Structure 1998, 6, 89-100.
124. Bird, L. E.; Subramanya, H. S.; Wigley, D. B. Helicases: a unifying structural theme? Curr. Opin. Struct. Biol. 1998, 8, 14-18.
125. Cho, H. S.; Ha, N. C.; Kang, L. W.; Chung, K. M.; Bac, S. H.; Jang, S. K.; Oh, B. H. Crystal structure of RNA helicase from genotype 1b hepatitis C virus. A feasible mechanism of unwind-ing duplex RNA. J. Biol. Chem. 1998, 273, 15045-15052.
126. Theis, K.; Chen, P. J.; Skorvaga, M.; Van Houten, B.; Kisker, C. Crystal structure of UvrB, a DNA helicase adapted for nucleotide excision repair. EMBO J. 1999, 18, 6899-6907.
127. Kadare, G.; Haenni, A.-L. Virus-encoded RNA helicases. J. Virol. 1997, 71, 2583-2590.
128. Gorbalenya, A. E.; Kunin, E. V. Viral proteins containing the purine NTP-binding sequence pattern. Nucleic Acids Res. 1989, 17, 8413-8440.
129. Tai, C. L.; Chi, W. K.; Chen, D. S.; Hwang, L. H. The helicase activity associated with hepatitis C virus nonstructural protein 3 (NS3). J. Virol. 1996, 70, 8477-8484.
130. Frick, D. N. Helicases as antiviral drug targets. Drug News Perspect. 2003, 16, 355-362.
131. Borowski, P.; Mueller, O.; Niebuhr, A.; Kalitzky, M.; Hwang, L.-H.; Schmitz, H.; Siwecka, M. A.; Kulikowski, T. ATP-binding domain of NTPase/helicase as a target for hepatitis C antiviral therapy. Acta Biochim. Pol. 2000, 47, 173-180.
132. Borowski, P.; Deinert, J.; Schalinski, S.; Bretner, M.; Ginalski, K.; Kulikowski, T.; Shugar, D. Halogenated benzimidazoles and benzotriazoles as inhibitors of the NTPase/helicase activities of hepatitis C and related viruses. Eur. J. Biochem. 2003, 270, 1645-1653.
133. Zhang, N.; Chen, H.-M.; Koch, V.; Schmitz, H.; Liao, C.-L.; Bretner, M.; Bhadti, V. S.; Fattom, A. I.; Naso, R. B.; Hosmane, R. S.; Borowski, P. Ring-expanded ("fat") nucleoside and nucleotide analogues exhibit potent in vitro activity against flaviviridae NTPases/helicases, including those of the West Nile virus, hepatitis C virus, and Japanese encephalitis virus. J. Med. Chem. 2003, 46, 4149-4164.
134. Kuang, W.-F.; Lin, Y.-C.; Jean, F.; Huang, Y.-W.; Tai, C.-L.; Chen, D.-S.; Chen, P.-J.; Hwang, L.-H. Hepatitis C virus NS3 RNA helicase activity is modulated by the two domains of NS3 and NS4A. Biochem. Biophys. Res. Commun. 2004, 317, 211-217.
135. Phoon, C. W.; Ng, P. Y.; Ting, A. E.; Yeo, S. L.; Sim, M. M. Biological evaluation of hepatitis C virus helicase inhibitors. Bioorg. Med. Chem. Lett. 2001, 11, 1647-1650.
136. Lun, L.; Sun, P. M.; Trubey, C. M.; Bachur, N. R. Antihelicase action of CI-958, a new drug for prostate cancer. Cancer Chemother. Phramacol. 1998, 42, 447-453.
137. Zhu, K.; Henning, D.; Iwakuma, T.; Valdez, B. C.; Busch, H. Adriamycin inhibits human RH II/Gu RNA helicase activity by binding to its substrate. Biochem. Biophys. Res. Commun. 1999, 266, 361-365.
138. Bachur, N. R.; Yu, F.; Johnson, R.; Hickey, R.; Wu, Y.; Malkas, L. Helicase inhibition by anthracycline anticancer agents. Mol. Pharmacol. 1992, 41, 993-998.
139. Ito, T.; Tahara, S. M.; Lai, M. M. The 3′-untranslated region of hepatitis C virus RNA enhances translation from an internal ribosomal entry site. J. Virol. 1998, 72, 8789-8796.
140. Kamoshita, N.; Tsukiyama-Kohara, K.; Kohara, M.; Nomoto, A. Genetic analysis of internal ribosomal entry site on hepatitis C virus RNA: implication for involvement of the highly ordered structure and cell type-specific transacting factors. Virology 1997, 233, 9-18.
141. Zhao, W. Genetic analysis of the internal ribosomal entry site of hepatitis C virus. Ph.D. Dissertation, State University of New York, Stony Brook, NY, 2001 (AN 2002:594323).
142. Klinck, R.; Westhof, E.; Walker, S.; Afshar, M.; Collier, A.; Aboul-Ela, F. A potential RNA drug target in the hepatitis C virus internal ribosomal entry site. RNA 2000, 6, 1423-1431.
143. Rando, R.; Welch, E. Methods for identifying small molecules that bind specific RNA structural motifs and uses high-throughput screening of combinatorial librarys. WO 2002083953, 2002.
144. Le, S.-Y.; Zhang, K.; Maizel, J. V., Jr. RNA molecules with structure dependent functions are uniquely folded. Nucleic Acids Res. 2002, 30, 3574-3582.
145. Ikeda, M.; Sakai, T.; Tsuai, S.; Zuao, I.; Ryan, H.; Iyan, S.; Kai, Y.; Kako, Y.; Tsukada, I.; Yanagisawa, M. Preparation of ellagic acid analogs for prevention of C-type hepatitis. JP 08268890, 1996.
146. Wang, W.; Preville, P.; Morin, N.; Mounir, S.; Cai, W.; Siddiqui, M. A. Hepatitis C viral IRES inhibition by phenazine and phenazine-like molecules. Bioorg. Med. Chem. Lett. 2000, 10, 1151-1154.
147. Ryu, K.-J.; Lee, S.-W. Identification of the most accessible sites to ribozymes on the hepatitis C virus internal ribosome entry site. J. Biochem. Mol. Biol. 2003, 36, 538-544.
148. Kikuchi, K.; Fukuda, K.; Umehara, T.; Hwang, J.; Kuno, A.; Hasegawa, T.; Nishikawa, S. In vitro selection of RNA aptamers that bind to domain II of HCV IRES. Nucleic Acids Res., Suppl. 2002, 267-268.
149. Kikuchi, K.; Umehara, T.; Fukuda, K.; Hwang, J.; Kuno, A.; Hasegawa, T.; Nishikawa, S. Structure-inhibition analysis of RNA aptamers that bind to HCV IRES. Nucleic Acids Res., Suppl. 2003, 291-292.
150. Kikuchi, K.; Umehara, T.; Fukuda, K.; Hwang, J.; Kuno, A.; Hasegawa, T.; Nishikawa, S. RNA aptamers targeted to domain II of hepatitis C virus IRES that bind to its apical loop region. J. Biochem. 2003, 133, 263-270.
151. Witherell, G. W. ISIS-14803 Isis Pharmaceuticals. Curr. Opin. Invest. Drugs 2001, 2, 1523-1529.
152. Heptazyme. Drug News Perspect. 2000, 13, 112.
153. Urbani, A.; De Francesco, R.; Steinkuhler, C. In Proteases of Infectious Agents; Dunn, B. M., Ed.; Academic Press: San Diego, CA, 1999; pp 61-91.
154. Wilkinson, C. S. Hepatitis C virus NS2-3 proteinase. Biochem. Soc. Trans. 1997, 25, S611.
155. Santolini, E.; Pacini, L.; Fipaldini, C.; Migliaceio, G.; Monica, N. The NS2 protein of hepatitis C virus is a transmembrane polypeptide. J. Virol. 1995, 69, 7461-7471.
156. Darke, P. L.; Jacobs, A. R.; Waxman, L.; Kuo, L. C. Inhibition of hepatitis C virus NS2/3 processing by NS4A peptides. Implications for control of viral processing. J. Biol. Chem. 1999, 274, 34511-34514.
157. Kim, J. L.; Morgenstern, K. A.; Lin, C.; Fox, T.; Dwyer, M. D.; Landro, J. A.; Chambers, S. P.; Markland, W.; Lepre, C. A.; O'Malley, E. T.; Harbeson, S. L.; Rice, C. M.; Murcko, M. A.; Caron, P. R.; Thomson, J. A. Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide. Cell 1996, 87, 343-355.
158. Yan, Y.; Li, Y.; Munshi, S.; Sardana, V.; Cole, J. L.; Sardana, M.; Steinkuehler, C.; Tomei, L.; De Francesco, R.; Kuo, L. C.; Chen, Z. Complex of NS3 protease and NS4A peptide of BK strain hepatitis C virus: a 2.2 Å resolution structure in a hexagonal crystal form. Protein Sci. 1998, 7, 837-847.
159. Pileri, P.; Uematsu, Y.; Campagnoli, S.; Galli, G.; Falugi, F.; Petracca, R.; Weiner, A. J.; Houghton, M.; Rosa, D.; Grandi, G.; Abrignani, S. Binding of hepatitis C virus to CD81. Science 1998, 282, 938-941.
160. Kitadokoro, K.; Bordo, D.; Galli, G.; Petracca, R.; Falugi, F.; Abrignani, S.; Grandi, G.; Bolognesi, M. CD81 extracellular domain 3D structure: insight into the tetraspanin superfamily structural motifs. EMBO J. 2001, 20, 12-18.
161. Wunschmann, S.; Medh, J. D.; Klinzmann, D.; Schmidt, W. N.; Stapleton, J. T. Characterization of hepatitis C virus (HCV) and HCV E2 interactions with CD81 and the low-density lipoprotein receptor. J. Virol. 2000, 74, 10055-10062.
162. Meola, A.; Sbardellati, A.; Bruni Ercole, B.; Cerretani, M.; Pezzanera, M.; Ceccacci, A.; Vitelli, A.; Levy, S.; Nicosia, A.; Traboni, C.; McKeating, J.; Scarselli, E. Binding of hepatitis C virus E2 glycoprotein to CD81 does not correlate with species permissiveness to infection. J. Virol. 2000, 74, 5933-5938.
163. Flint, M.; Maidens, C.; Loomis-Price, L. D.; Shotton, C.; Dubuisson, J.; Monk, P.; Higginbottom, A.; Levy, S.; McKeating, J. A. Characterization of hepatitis C virus E2 glycoprotein interaction with a putative cellular receptor, CD81. J. Virol. 1999, 73, 6235-6244.
164. Tseng, C.-T. K.; Klimpel, G. R. Binding of the hepatitis C virus envelope protein E2 to CD81 inhibits natural killer cell functions. J. Exp. Med. 2002, 195, 43-49.
165. Crotta, S.; Stilla, A.; Wack, A.; D'Andrea, A.; Nuti, S.; D'Oro, U.; Mosca, M.; Filliponi, F.; Brunetto, R. M.; Bonino, F.; Abrignani, S.; Valiante, N. M. Inhibition of natural killer cells through engagement of CD81 by the major hepatitis C virus envelope protein. J. Exp. Med. 2002, 195, 35-41.
166. Andre, P.; Komurian-Pradel, F.; Deforges, S.; Perret, M.; Berland, J. L.; Sodoyer, M.; Pol, S.; Brechot, C.; Paranhos-Baccala, G.; Lotteau, V. Characterization of low- and very-low-density hepatitis C virus RNA-containing particles. J. Virol. 2002, 76, 6919-6928.